Clinical

British Journal of Cancer (2003) 89, 615–616. doi:10.1038/sj.bjc.6601137 www.bjcancer.com
Published online 12 August 2003

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports

K Brickell1, D Porter1 and P Thompson1

1Oncology Department, Auckland Hospital, Private Bag 92024, Auckland 1, New Zealand

Correspondence: Dr P Thompson, E-mail: paulT@adhb.govt.nz

Received 8 April 2003; Accepted 15 May 2003.

Top

Abstract

Interactions between phenytoin and the fluoropyrimidine derivatives, 5 fluorouracil (5FU) and capecitabine, are not commonly documented or widely recognised. As more people with significant medical comorbidities are now being considered for chemotherapy, it is increasingly likely that people receiving phenytoin will be prescribed treatment with fluoropyrimidines. We present two cases of clinical phenytoin toxicity occurring after starting treatment with 5-fluorouracil/folinic acid (5FU/FA) and a third who developed clinical phenytoin toxicity after starting capecitabine (an orally administered prodrug of fluorouracil).

Keywords:

phenytoin, fluoropyrimidine, fluorouracil, capecitabine